| abstract |
Pyrimidines of formla (1) are described: n n n wherein R 1 is a —XR 6 group; n R 2 and R 3 which may be the same or different is each a hydrogen or halogen atom or a group selected from an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, —OH, —OR 10 [where R 10 is an optionally substituted aliphatic, cycloaliphatic, heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group] —SH, —NO 2 , —CN, —SR 10 , —COR 10 , S(O)R 10 , —SO 2 R 8 , —SO 2 N(R 8 )(R 9 ), —CO 2 R 8 , —CON(R 8 )(R 9 ), —CSN(R 8 )(R 9 ), —NH 2 or substituted amino group; n R 4 is a X 1 R 11 group where X 1 is a covalent bond or a —C(R 12 )(R 13 )— [where each of R 12 and R 13 is a hydrogen or halogen atom or a hydroxyl, alkyl or haloalkyl group] or —C(O)— group and R 11 is an optionally substituted phenyl, thienyl, thiazolyl or indolyl group; n R 5 is a halogen atom or an alkynyl group; n and the salts, solvates, hydrates and N-oxides thereof. n The compounds are selective KDR kinase and/or FGFr kinase inhibitors and are of use in the prophylaxis and treatment of disease states associated with angiogenesis |